Ordinary Adjustment | Solactive Pharma Breakthrough Value Index | Effective Date 22nd September 2025
Solactive Pharma Breakthrough Value Index:
In the ordinary adjustment, the following composition will be implemented effective open 22nd September 2025:
| AGIOS PHARMACEUTICALS INC |
| ALNYLAM PHARMACEUTICALS INC |
| ARGENX SE – ADR |
| BASILEA PHARMACEUTICA LTD |
| BEONE MEDICINES LTD-ADR |
| BIOGEN INC |
| BIOMARIN PHARMACEUTICAL INC |
| BRIDGEBIO PHARMA INC |
| CATALYST PHARMACEUTICALS INC |
| CHUGAI PHARMACEUTICAL CO LTD ORD |
| EISAI |
| GENMAB A/S |
| HALOZYME THERAPEUTICS INC |
| INCYTE CORP |
| INNOCARE PHARMA LTD |
| IONIS PHARMACEUTICALS INC |
| IPSEN SA |
| KYOWA KIRIN CO LTD |
| LG CHEM LTD |
| LIGAND PHARMACEUTICALS INC |
| MESOBLAST LIMITED SPONSORED ADR |
| MIRUM PHARMACEUTICALS INC |
| NIPPON SHINYAKU CO LTD |
| PHARMA MAR SA |
| PHARMING GROUP NV |
| PTC THERAPEUTICS INC |
| ROYALTY PHARMA PLC- CL A |
| SWEDISH ORPHAN BIOVITRUM AB |
| TRAVERE THERAPEUTICS INC |
| ULTRAGENYX PHARMACEUTICAL INC |
| UNITED THERAPEUTICS CORP |
| VERTEX PHARMACEUTICALS INC |
| XENCOR INC |
| XERIS BIOPHARMA HOLDINGS INC |
| ZAI LAB LTD |
| ZEVRA THERAPEUTICS INC |